logo-loader

Fusion Antibodies plunges after significant lowering of forecast for 2019 financial year

Published: 08:39 13 Aug 2018 BST

Antibodies
The company said it still expected to achieve “modest year on year revenue growth”

Fusion Antibodies PLC (LON:FAB) shares plunged in early trading Monday after it said that its results for the 2019 financial year would be “significantly behind current market expectations”.

The AIM-listed antibody developer said in an update that while trading for the 2018 financial year is in line with market expectations, delays in securing some large contracts, in addition to slower than anticipated trading in the current financial period had led to the downgrade in its predictions for 2019.

Modest year-on-year revenue growth expected

Despite the lowering of forecasts, the company said it still expected to achieve “modest year on year revenue growth”, adding that it had completed its laboratory capacity extension.

Fusion Antibodies shares were down 32.9% at 81.5p.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

20 minutes ago